MERCK & CO., INC.

(MRK)
  Report
Delayed Nyse  -  05/20 04:03:28 pm EDT
93.55 USD   +1.59%
05/20Merck's Keytruda Receives Positive EMA Panel Opinion as Adjuvant Therapy in Skin Cancer
MT
05/20Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
BU
05/20Merck Gets CHMP Backing for Expanded Keytruda Use in Melanoma
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analysis
Warren Buffett's latest shopping spree
Let's have a look at the latest moves in the US listed positions of Warren Buffett's holding company : Berkshire Hathaway. The purpose of this article is to allow you to follow the latest decisions...
More Must read
Stock Pick
Merck and Company : Leader in oncology, modest valuation
With $46 billion in expected revenue this year, the American company Merck ranks sixth among the world's major pharmaceutical groups, behind J&J .
More Recommendations
Official Publications
Upcoming event on MERCK & CO., INC.